Theravance, Inc. (THRX)
$13.66
-0.38 (-2.71%)
| CAPS Rating |
|
|---|---|
| Open | $14.25 |
| Previous Close | $14.04 |
| Daily Range | $13.40 - $14.39 |
| 52-Week Range | $4.32 - $18.56 |
| Market Cap | $868.26M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 275,035 |
| Average Daily Volume | 278,000 |
How do you think THRX will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
THRX Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
THRX News and Commentary
- Sell Dendreon! No, Buy Dendreon! – The Motley Fool
- Rocket Stock or Dud? – The Motley Fool
- Dyax: A Cinderella Story Ends in a Fall – The Motley Fool
- Wyeth: Now Approved to Kill More Bugs! – The Motley Fool
- Taking the F Out of FDA – The Motley Fool
- Roses and Candy From the FDA? – The Motley Fool
- Not If, but When, for Lilly – The Motley Fool
- The FDA Needs a Bake Sale – The Motley Fool
- The FDA's Killing Bug Killers – The Motley Fool
- Updated FDA Calendar of 75 Decision Dates – Blog at The Motley Fool
- One Share Offering Too Many for Vertex? – The Motley Fool
- Johnson & Johnson Gets Rejected – The Motley Fool
- No Love for Antibiotics From the FDA – The Motley Fool
- Discovery's Costly Debt Delay – The Motley Fool
- 5 Deathbed Stocks – The Motley Fool
- The FDA's Call for Cash – The Motley Fool
- FDA's Mixed Signals for Theravance – The Motley Fool
- Resources for Rx Stocks – The Motley Fool
- Seattle Genetics' Good Timing – The Motley Fool
- Better Safe Than Sorry at Theravance – The Motley Fool


RSS Headlines
Fool UK